Biocon's shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to 'Buy' with a target price of ₹430, ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.

HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Motilal Oswal (MOSL) has reiterated its "Buy" rating on HCL Technologies, setting a target price of Rs 2,400, which implies a ...

Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck ...

The market may attempt a rebound amid likely consolidation; however, the overall sentiment remains bearish. Below are some ...

So, buy-on decline to continue over here, but just for intraday perspective, overall swings will continue and one needs to be ...

Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...